Biomea Fusion, Inc. (BMEA)
After hours:
| Previous close | 10.46 |
| Open | 10.64 |
| Bid | 10.47 x 300 |
| Ask | 10.53 x 100 |
| Day's range | 10.38 - 10.83 |
| 52-week range | 8.12 - 43.69 |
| Volume | |
| Avg. volume | 1,006,028 |
| Market cap | 378.137M |
| Beta (5Y monthly) | -0.35 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.55 |
| Earnings date | 01 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 53.00 |
GlobeNewswireBiomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cellsREDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, today announced the completion of enrollment of the first three dose exp
Simply Wall St.Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GlobeNewswire
Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights
Reported positive data from the escalation portion of Phase 1/2 study (COVALENT-111) in type 2 diabetes patients, displaying durable improved glycemic control while off therapy for 22 weeks, supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes: a loss of healthy, insulin-producing beta cellsAnnounced initial clinical data from our Phase 2 study (COVALENT-112) in type 1 diabetes from the first two type 1 diabetes patients dosed with BMF-219 and demonstrated ea
